Since the VHL E3 ligase is poorly expressed in platelets, BCL-XL PROTACs targeted for degradation by that ligase do not induce thrombocytopenia, maintaining the same therapeutic efficacy as VHL is expressed in the lymphomatous cells [68]. This evidence concerns the gene BCL2L1 and Thrombocytopenia.